CD104 (Integrin Beta-4) (Squamous Cell Carcinoma Antigen) Antibody - With BSA and Azide
Purified Mouse Monoclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application ![]()
| WB, IHC, IF, FC, IP, E |
---|---|
Primary Accession | P16144 |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Isotype | IgG2a, kappa |
Clone Names | UM-A9 |
Calculated MW | 205kDa |
Gene ID | 3691 |
---|---|
Other Names | Integrin beta-4, GP150, CD104, ITGB4 |
Target/Specificity | Human squamous cell carcinoma (UM-SCC1) |
Application Note | ELISA : For coating, order antibody without BSA Flow Cytometry : 0.5-1ug/million cells Immunofluorescence : 1-2ug/ml Immunoprecipitation (1-2ug/500ug protein) (precipitates active CDK1/cyclin B1 complexes); Western Blotting : 0.5-1.0 µg/ml Immunohistology (Frozen) : 1-2ug/ml for 30 min at RT. |
Format | 0.5 ml at 200ug/ml with BSA and azide |
Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
Precautions | CD104 (Integrin Beta-4) (Squamous Cell Carcinoma Antigen) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | ITGB4 |
---|---|
Function | Integrin alpha-6/beta-4 is a receptor for laminin. Plays a critical structural role in the hemidesmosome of epithelial cells. Is required for the regulation of keratinocyte polarity and motility. ITGA6:ITGB4 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGA6:ITGB4 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:22351760). |
Cellular Location | Cell membrane; Single-pass type I membrane protein. Cell membrane; Lipid-anchor. Cell junction, hemidesmosome. Note=Colocalizes with DST at the leading edge of migrating keratinocytes |
Tissue Location | Integrin alpha-6/beta-4 is predominantly expressed by epithelia. Isoform beta-4D is also expressed in colon and placenta. Isoform beta-4E is also expressed in epidermis, lung, duodenum, heart, spleen and stomach |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abgent.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Recognizes a protein of 205kDa, which is identified as integrin beta-4 (ITGB4). Its epitope is localized in the extracellular domain of ITGB4 protein. Integrins are heterodimers comprised of alpha and beta subunits, that are non-covalently associated transmembrane glycoprotein receptors. Different combinations of alpha and beta polypeptides form complexes that vary in their ligand-binding specificities. Integrins mediate cell-matrix or cell-cell adhesion, and transduced signals that regulate gene expression and cell growth. This gene encodes the integrin beta-4 subunit, a receptor for the laminins. This subunit tends to associate with alpha-6 subunit and is likely to play a pivotal role in the biology of invasive carcinoma. Mutations in this gene are associated with epidermolysis bullosa with pyloric atresia. Multiple alternatively spliced transcript variants encoding distinct isoforms have been found for this gene.
References
1. Signal transduction by the alpha 6 beta 4 integrin: distinct beta 4 subunit sites mediate recruitment of Shc/Grb2 and association with the cytoskeleton of hemidesmosomes. Mainiero F, Pepe A, Wary KK, Spinardi L, Mohammadi M, Schlessinger J, Giancotti FG. EMBO J. 1995;14(18):4470-81.
2. The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4. Van Waes C, Kozarsky KF, Warren AB, Kidd L, Paugh D, Liebert M, Carey TE. Cancer Res. 1991;51(9):2395-402.
3. Altered expression in squamous carcinoma cells of an orientation restricted epithelial antigen detected by monoclonal antibody A9. Kimmel KA, Carey TE. Cancer Res. 1986 Jul;46(7):3614-23.

If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.